<DOC>
	<DOCNO>NCT02368860</DOCNO>
	<brief_summary>This exploratory Phase I study assess safety tolerability OXIRI regimen [ oxaliplatin ( O ) , xeloda ( X ) irinotecan ( I ) ] evaluate preliminary evidence efficacy , patient advance and/or metastatic pancreatic adenocarcinoma . The investigator hypothesize 2 3 weekly dos oxaliplatin genotype directed-dosing irinotecan combination chronomodulated capecitabine ( xeloda ) administer continuously tolerable FOLFIRINOX regimen ( folinic acid , fluorouracil , irinotecan oxaliplatin ) maintain anti-tumour activity .</brief_summary>
	<brief_title>OXIRI Oxaliplatin ( O ) , Xeloda ( X ) Irinotecan ( I ) Pancreatic Adenocarcinoma</brief_title>
	<detailed_description>This study comprise dose escalation phase use 3+3 design determine safety , tolerability pharmacokinetics OXIRI regimen expansion phase evaluate MTD determine early sign efficacy . Eligible patient receive novel chemotherapeutic regimen ( OXIRI regimen ) xeloda administer chronomodulated fashion dose irinotecan guide UGT1A1*28 UGT1A1*6 genotype status patient .</detailed_description>
	<mesh_term>Adenocarcinoma</mesh_term>
	<mesh_term>Pancreatic Neoplasms</mesh_term>
	<mesh_term>Capecitabine</mesh_term>
	<mesh_term>Oxaliplatin</mesh_term>
	<mesh_term>Irinotecan</mesh_term>
	<mesh_term>Camptothecin</mesh_term>
	<criteria>1 . Patients 21 75 year age 2 . A histopathologically cytological confirm diagnosis locally advance and/or metastatic PDAC unresectable 3 . Measurable disease per Response Evaluation Criteria Solid Tumors ( RECIST ) ver 1.1 criterion 4 . Life expectancy least 12 week 5 . Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 6 . Adequate hematologic function ( neutrophils count ≥ 1.5 × 109/L , platelet count ≥ 100 × 109/L ) 7 . Adequate hepatic function ( total bilirubin ≤ 1.5 x upper limit normal ( ULN ) , aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤ 3 x ULN 8 . Adequate renal function ( calculated creatinine clearance &gt; 50 mL/min ) 9 . Able give inform consent 10 . Toxicity relate previous radiotherapy chemotherapy resolve ≤ Grade 1 1 . History prior malignancy except nonmelanoma skin cancer within last 5yrs 2 . Uncontrolled central nervous system ( CNS ) metastases carcinomatous meningitis 3 . Uncontrolled concomitant medical illness ( e.g . hypertension , myocardial infarct , heart failure , ventricular arrhythmia , diabetes , severe infection ) 4 . Major surgery within four week prior study treatment 5 . Patients chronic immunosuppressive therapy 6 . Pregnant breastfeed female patient 7 . On anticoagulant therapy vitamin K antagonists . 8 . Doseescalation cohort : Patients homozygous uridine diphosphate glucuronosyltransferase ( UGT ) 1A1*6/*6 UGT1A1*28/*28 Previous oxaliplatin irinotecan chemotherapy Treatment follow anticancer therapy prior first dose OXIRI within state timeframes Cyclical chemotherapy within period time short cycle length use treatment . Exception weekly chemotherapy regimen , minimum 2 week washout last dose require . Biological therapy ( e.g. , antibody ) within period time ≤ 5 t1/2 ≤ 4 week , whichever short , prior start study drug Continuous intermittent small molecule therapeutic within period time ≤ 5 t1/2 ≤ 4 week ( whichever short ) prior start study drug Any investigational agent within period time ≤ 5 t1/2 less cycle length use treatment ≤ 4 week ( whichever shortest ) prior start study drug Wide field radiotherapy ≤ 4 week limited field radiation palliation ≤ 2 week prior start study drug 9 . Doseexpansion cohort : Previous chemotherapy radiotherapy</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>